Odalasvir

DRUG2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Hepatitis C, ChronicRenal Insufficiency

Phase 1

A Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir

CompletedNCT02961660

Janssen Research & Development, LLCRenal Insufficiency

Start: 2016-11-09End: 2018-04-09Updated: 2025-02-03

Phase 2

Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection

CompletedNCT02765490

Janssen Research & Development, LLCHepatitis C, Chronic

Start: 2016-11-09End: 2017-11-16Updated: 2019-11-20

Related Papers

JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study.

2020-02-173 citations

JNJ‐4178 (AL‐335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus‐Infected Patients Without Cirrhosis: OMEGA‐1

Hepatology2019-01-298 citations